Insights

2 top blue chip ASX 200 shares rated as buys

Looking for blue chips? Check out these highly rated shares…
The post 2 top blue chip ASX 200 shares rated as buys appeared first on The Motley Fool Australia. –

Are you wanting to buy some blue chip ASX shares for your portfolio? Then you might want to check out the ones listed below.

These quality companies have been tipped as blue chips to buy. Here’s what you need to know:

ResMed Inc. (ASX: RMD)

The first blue chip for investors to consider is ResMed. It is a medical device company with a focus on sleep disorders.

ResMed has continued to grow at a decent rate over the last 12 months despite the pandemic’s negative impact on sleep disorder diagnoses and referrals. The good news is that with vaccines rolling out, referrals are expected to pick up again in FY 2022. And with one of its largest rivals recently having to recall an extremely popular sleep apnoea device, the company has been tipped to win further market share and continue its growth.

Looking further ahead, the company still has a very long runway for growth over the next decade. In fact, management has set itself a goal of improving 250 million lives in out-of-hospital healthcare in 2025. Helping it achieve this goal will be its high quality product portfolio, rapidly growing digital health ecosystem, and the growing awareness of sleep disorders and their impact on a person’s overall health.

Earlier today, Macquarie upgraded the company’s shares to an outperform rating with a $34.85 price target.

Sonic Healthcare Limited (ASX: SHL)

A second blue chip share to look at is Sonic Healthcare. It is a leading medical diagnostics company with operations across the world.

Unlike ResMed, Sonic has had the wind in its sails over the last 12 months. This led to the company reporting a 33% increase in half year revenue to $4.4 billion and a 166% jump in first half net profit to $678 million in February.

This was driven largely by strong demand for COVID-19 testing services. However, it is worth acknowledging that the rest of the business has been performing positively as well since trading conditions returned to relatively normal.

One broker that is a fan of the company is Credit Suisse. It currently has an outperform rating and $40.00 price target on Sonic’s shares.

The broker is seeing signs of pent up demand for healthcare services after people delayed seeking healthcare during the pandemic. It expects Sonic to benefit from this, along with further COVID-19 testing in the near term.

The post 2 top blue chip ASX 200 shares rated as buys appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of May 24th 2021

More reading

Why Actinogen, Novonix, ResMed, & Zip shares are pushing higher

ASX 200 down 0.5%: Costa’s acquisition, Afterpay & Zip charge higher

Top brokers name 3 ASX shares to buy today

3 top ASX shares in sector selling at 30% discount: expert

ASX 200 Weekly Wrap: ASX makes it 5 out of 5

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. and Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!